MICA and neoplasm: We then evaluated the therapeutic effect of MICAB1 mIgG2a mAb on tumor models based on subcutaneous (s.c.)injection of B16F10-MICA*001 in immunocompetent MICAgen transgenic mice34 (Figure 3c and d).